Welcome
Support Centre
03 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
To Compare Intravenous Treosulphan with Intravenous Treosulphan plus Cisplatin in Advanced Ovarian Cancer
ISRCTN ISRCTN59482963
ClinicalTrials.gov identifier
Public title To Compare Intravenous Treosulphan with Intravenous Treosulphan plus Cisplatin in Advanced Ovarian Cancer
Scientific title
Acronym N/A
Serial number at source O10
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Ovarian cancer
Participants - inclusion criteria 1. International Federation of Gynecology and Obstetrics (FIGO) stage Ic or II (except well differentiated), III or IV ovarian cancer
2. Histological confirmation of carcinoma of epithelial origin
3. Aged 75 or under
4. Life expectancy >2 months
5. No extensive prior chemotherapy (no prior treosulfan or cisplatin at all, and not more than one course of other cytotoxic treatment)
6. No radical prior radiotherapy to pelvis and/or abdomen within preceding 3 months
7. No depressed marrow function or gastro-intestinal bleeding
8. Good renal function
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/1993
Anticipated end date 01/08/1995
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Patients are randomised to one of two treatment arms:
1. Arm A: Treosulphan given every 3 weeks
2. Arm B: Treosulphan plus cisplatin repeated every 3 weeks
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Leo Pharmaceuticals (UK)
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 20 7670 4723
  Fax +44 (0) 20 7670 4818
  Email register@ctu.mrc.ac.uk
Sponsor Leo Pharmaceuticals (UK)
  Address Longwick Road
  City/town Princes Risborough
  Zip/Postcode HP27 9RR
  Country United Kingdom
  Tel +44 (0) 1844 347333
  Email
  Sponsor website: http://www.leo-pharma.co.uk/w-site/leo-gb/docs-gb.nsf
Date applied 19/08/2002
Last edited 27/05/2008
Date ISRCTN assigned 19/08/2002
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central